IgA nephropathy

In some patients with IgA nephropathy (IgAN), intraglomerular coagulation plays a role in depositing fibrinogen (235,236). IgAN patients treated with urokinase show a marked improvement in urinary protein concentration, semm creatinine, and blood urea nitrogen levels (237). 

Glomerular diseases (e.g., anti-glomerular basement membrane disease, focal segmental glomerularsclerosis, IgA nephropathy, hemolytic uremic syndrome, systemic lupus erythematosus, Alport s syndrome, amyloidosis, membranous nephropathy, and Goodpasture s syndrome)... 

A number of studies in humans show that PUFAs can generate significant immunomodulatory effects. Generally, these studies have utilized considerably lower amounts of fish oil to treat subjects than found in most animal studies. Numerous clinical trials have examined the effects of fish oil on rheumatoid arthritis and many have reported statistically significant benefits such as decreased morning stiffness and numbers of tender joints [57]. Several other studies have reported that PUFAs can provide therapeutic benefits for patients with IgA nephropathy, the most common primary human glomerulonephritis... 

Pestka, J. J. Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal immune response with systemic repercussions. Toxicol. Lett. 140-141, 287, 2003. 

The ACE gene encodes two isozymes (somatic ACE isozyme and germinal ACE isozyme). ACE is a membrane-bound enzyme on the surface of vascular endothelial cells that also circulates in plasma and shows great individual variability determined by an I/D polymorphism in intron 16 of the ACE gene (ACE-I/D polymorphism). More than 160 ACE polymorphisms have been reported, 34 of which are located in coding regions, and 18 are missense mutations (606). ACE-related polymorphic variants have been associated with hypertension, atherosclerosis, stroke, left ventricular hypertrophy, chronic renal failure in IgA nephropathy, Henoch-Schonlein purpura nephritis, mechanical efficiency of skeletal muscle, intracranial aneurysms, susceptibility to myocardial infarction, diabetic nephropathy, AD, and longevity (12,606,607). 

III.b.2. IgA Nephropathy (Berger s Disease) and Henoch—Schonlein Purpura... 

Samuels JA, Strippoli GEM, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003. 

Winters MJ, Hurley RM, Lirenman DS. ANCA-positive glomerulonephritis and IgA nephropathy in a patient on propylthiouracil. Pediatr Nephrol 2002 17(4) 257-60. 

Nl. Nakamura, T., Ushiyama, C., Suzuki, S., Hara, M., Shimada, N., Sekizuka, K., Ebihara, I., and Koide, H., Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am. J. Nephrol. 20, 373-379 (2000). 

Kidney urine IgA nephropathy Mouse model (Blab/c and hyper IgA vs control) MALDI-QIT-TOF MS LC-LTQ MS Specific lipid signature in the tubular lesion of hyper-IgA mice (63)... 

In 54 patients, a kidney biopsy was performed 13.2 8.9 days after onset (n = 32). In all patients, the findings suggested either acute tubular necrosis or its recovery phase. The underlying diseases included kidney diseases such as IgA nephropathy [138], minimal change nephrotic syndrome [139], autosomal dominant polycystic kidney disease (ADPKD) [140], and cystinuria [67]. 

Ots M, Uibo O, Metskula K, Uibo R, Salupere V. IgA-antigliadin antibodies in patients with IgA nephropathy The secondary phenomenon Am J Nephrol 1999 19 453-458. 

Roccatello D, Picciotto G, Ropolo R, et al. Kinetics and fate of IgA-IgG aggregates as a model of naturally occurring immune complexes in IgA nephropathy. Lab Invest 1992 66(l) 86-95. 

Ding FI, Fie Y, Li K, Yang J, Li X, Lu R, Gao W. Urinary neutrophol gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulaointerstitial injury in IgA nephropathy. Clin Immunol 2007 123 227-234. 

Ranlerl E, Gesualdo L, Petrarulo E, Schena FP Urinary IL-6/EGF ratio a useful prognostic marker of renal damage In IgA nephropathy. Kidney Int 1996 50 1990-2001. 

WatanabeY, inoueT,Okada H, KotakiS, KannoY,KikutaT, Suzuki Himpactofselectingene polymorphisms on rapid progression to end-stage renal disease in patients with IgA nephropathy. Intern Med. 2006 45 947-51. 

Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating igA nephropathy, Nephrol Dial Transplant 2004,19 2155... 

During the past decade a number of case reports have described the occurrence of different forms of renal disease in patients exposed to silica [58-66]. However, only a few reports concerned subjects exposed to sihca but without silicosis. Most of the cases demonstrated renal lesions compatible with rapidly progressive glomerulonephritis with a necrotizing component present in most cases. Crescent formation was described in a patient with proliferative glomerulonephritis [59] and three individuals with IgA nephropathy [60]. 

R. Coppo and Dr. L. Peruzzi (Eds.), Moderately Proteinuric IgA Nephropathy in the Young... 

BaHardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002 13 142-8. 

---